Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice

Neurobiology of Disease

Volumn 21, Issue 1, 2006, Pages 237-245

  Avraham, Yosefa ^a   Israeli, Eran ^b   Gabbay, Ezra ^b   Okun, Avital ^a   Zolotarev, Olga ^a   Silberman, Isable ^a   Ganzburg, Vera ^a   Dagon, Yossi ^a   Magen, Iddo ^a   Vorobia, Lia ^a   Pappo, Orit ^b   Mechoulam, Raphael ^c   Ilan, Yaron ^b   Berry, Elliot M ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Activity score; Cannabinoid receptors; Endocannabinoids; Hepatic encephalopathy; Neurological and cognitive functions; Thioacetamide

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; BRAIN PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; NOLADIN; RIMONABANT; SR 144528A; THIOACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HEPATIC ENCEPHALOPATHY; LIVER DISEASE; LIVER FAILURE; MOUSE; NEUROPSYCHIATRY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ARACHIDONIC ACIDS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HEPATIC ENCEPHALOPATHY; LIVER; LIVER FAILURE, ACUTE; MAZE LEARNING; MICE; MICE, INBRED STRAINS; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; THIOACETAMIDE;

EID: 29144480571     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.07.008     Document Type: Article

References (60)

1. 1) receptors Psychopharmacology 132 1997 104 106
2. Y. Avraham, A. Ben Menachem, A. Okun, O. Zolotarav, N. Abel, R. Mechoulam, and E.M. Berry Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice Brain Res. Bull. 15 65 2005 117 123
3. A.S. Basile, and E.A. Jones Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy Hepatology 25 1997 1303 1305
4. A.S. Basile, R.D. Hughes, P.M. Harrison, Y. Murata, L. Panell, E.A. Jones, R. Williams, and P. Skolnick Elevated brain concentration of 1,4 benzodiazepines in fulminant hepatic failure N. Engl. J. Med. 325 1991 473 478
5. 1 receptors mediate the vasodialated state in advanced liver cirrhosis Nat. Med. 7 2001 827 832
6. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J. Neurosci. 23 2003 11136 11141
7. S. Ben-Shabat, E. Fride, T. Sheskin, T. Tamiri, M.H. Rhee, Z. Vogel, T. Bisogno, L. De Petrocellis, V. Di Marzo, and R. Mechoulam An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl glycerol cannabinoid activity Eur. J. Pharmacol. 353 1998 23 31
8. E.M. Berry, and R. Mechoulam Tetrahydrocannabinol and endocannabinoids in feeding and appetite Pharmacol. Ther. 95 2002 185 190
9. R.F. Butterworth Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems Curr. Opin. Neurol. 13 2000 721 727
10. 2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation Int. Immunopharmacol. 2 2002 69 82
11. Y. Chen, S. Constantini, V. Trembovler, M. Weinstock, and E. Shohami An experimental model of closed head injury in mice: pathophysiology, histopathology and cognitive deficits J. Neurotrauma 13 1996 557 568
12. P. Consroe Brain cannabinoid systems as targets for the therapy of neurological disorders Neurobiol. Dis. 5 1998 534 551
13. W.A. Devane, F.A. Dysarz, M.R. Johnson, L.S. Melvine, and A.C. Howlett Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 34 1988 605 613
14. W.A. Devane, L. Hanus, A. Breuer, R.G. Partwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mendelbaum, A. Etinger, and R. Mechoulam Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
15. A. Fernández-Martínez Thioacetamide-induced liver regeneration involves the expression of cyclooxygenase 2 and nitric oxide synthase 2 in hepatocytes J. Hepatol. 40 2004 963 970
16. G.J. Fitz Hepatic encephalopathy, hepatopulmonary syndromes, hepatorenal syndrome, coagulopathy and endocrine complications of liver diseases Sleisenger and Fordtran's Gastrointestinal and Liver Disease 7th ed. 2002 W.B. Saunders Press 1543 1565
17. E. Fride, and R. Mechoulam Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent Eur. J. Pharmacol. 231 1993 313 314
18. S.H. Gammal, A.S. Basile, D. Geller, P. Skolnick, and E.A. Jones Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands Hepatology 11 1990 371 378
19. Y. Gaoni, and R. Mechoulam Isolation, structure and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 86 1964 1646 1647
20. C. Goulenok, B. Bernard, J.F. Cadranel, D. Thabut, V. Di Martino, P. Opolon, and T. Poynard Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis Aliment. Pharmacol. Ther. 16 2002 361 372
21. A. Goutopoulos, and A. Makriyannis From cannabis to cannabinergics: new therapeutic opportunities Pharmacol. Ther. 95 2002 103 117
22. R.I. Grundy, M. Rabuffetti, and M. Beltramo Cannabinoids and neuroprotection Mol. Neurobiol. 24 2001 29 51
23. J.B. Hammond, and F. Ahmad Hepatic encephalopathy and role of antibenzodiazepines Am. J. Ther. 5 1998 33 36
24. 2), a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. 96 1999 14228 14233
25. 1 receptor Proc. Natl. Acad. Sci. 98 2001 3662 3665
26. L. Hanuš, Y. Avraham, D. Ben-Shushan, O. Zolotarev, E.M. Berry, and R. Mechoulam Short term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain Brain Res. 983 2003 144 151
27. S. Hao, Y. Avraham, O. Bonne, and E.M. Berry Separation-induced body weight loss impairment in alternation behaviour and autonomic tone: effects of tyrosine Pharmacol. Biochem. Behav. 67 2000 1 9
28. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. De Costa, and K.C. Rice Canabinoid receptor localization in brain Proc. Natl. Acad. Sci. 87 1990 1932 1936
29. AC. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, R.G. Pertwee, and International Union of Pharmacology Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
30. K. Ikejima, H. Honda, M. Yoshikawa, M. Hirose, T. Kitamura, Y. Takei, and N. Sato Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver Hepatology 36 2002 246 248
31. T.C. Kirkham, and C.M. Williams Synergistic effect of opioid and cannabinoid antagonists on food intake Psychopharmacology 153 2001 267 270
32. F.S. Larsen, and A.T. Blei Pathophysiology of cerebral edema in fulminant hepatic failure J. Hepatol. 31 1999 771 776
33. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, and J. Fernandez-Ruiz Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease Neurobiol. Dis. 19 2005 96 107
34. 1 cannabinoid receptors in human vascular endothelial cells Biochem. J. 346 2000 835 840
35. 1 cannabinoid receptors and on-demand defense against excitotoxicity Science 302 2003 84 88
36. B.R. Martin, R. Mechoulam, and R.K. Razdan Discovery and characterization of endogenous cannabinoids Life Sci. 65 1999 573 595
37. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
38. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, and D.R. Compton Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
39. R. Mechoulam, D. Panikashvili, and E. Shohami Cannabinoids and brain injury: therapeutic implication Trends Mol. Med. 8 2002 58 61
40. S. Munro, K. Thomas, and M. Abu Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 561 564
41. T. Nagayama, A.D. Sinor, R.P. Simon, J. Chen, S.H Graham, K. Jin, and D.A. Greenberg Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures J. Neurosci. 19 1999 2987 2995
42. D.S. Olton, and R.J. Samuelson Remembrance of places passed: spatial memory in rats J. Exp. Psychol., Anim. Behav. Processes 2 1976 97 116
43. D. Panikashvili, C. Simeonidou, S. Ben-Shabat, L. Hanus, A. Breuer, R. Mechoulam, and E. Shohami An endogenous cannabinoid (2-AG) is neuroprotective after brain injury Nature 413 2001 527 531
44. 2 receptors Pharmacol. Ther. 74 1997 129 180
45. C.G. Pick, and J. Yanai Eight arm maze for mice Int. J. Neurosci. 21 1983 63 66
46. G. Pomier-Layrargues, J.F. Giguere, J. Lavoie, P. Perney, S. Gagnon, M. D'Amour, J. Wells, and R.F. Butterworth Flumazenil in cirrhotic patients in hepatic coma: a randomized double blind placebo-controlled crossover trial Hepatology 19 1994 32 37
47. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Neliat, D. Caput, P. Ferrara, P. Soubrie, J.C. Breiere, and G. Le Fur SR141716A a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240 244
48. 2 cannabinoid receptor J. Pharmacol. Exp. Ther. 284 1998 644 650
49. R. Ros, J. Claria, J. To-Figueras, A. Planaguma, P. Cejudo-Martin, G. Fernandez-Varo, R. Martin-Ruiz, V. Arroyo, F. Rivera, J. Rodes, and W. Jimenez Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat Gastroenterology 122 2002 85 93
50. J. Schnur, J. Olah, A. Szepesi, P. Nagy, and S.S. Thorgeirsson Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice Eur. J. Gastroenterol. Hepatol. 16 2004 127 133
51. D. Shawcross, and R. Jalan Dispelling myths in the treatment of hepatic encephalopathy Lancet 365 2005 431 433
52. A.D. Sinor, S.M. Irvin, and D.A. Greenberg Endocannabinoids protect cortical neurons from in vitro ischemia in rats Neurosci. Lett. 278 2000 157 160
53. T. Sugiura, N. Yoshinaga, S. Kondo, K. Waku, and Y. Ishima Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain Biochem. Biophys. Res. Commun. 271 2000 654 658
54. C.C. Van der Rijt, S.W. Schalm, J. Meulstee, and T. Stijnen Flumazenil therapy for hepatic encephalopathy. A double blind crossover study Gastroentrol. Clin. Biol. 19 1995 572 580
55. M. Van der Stelt, and V. Di Marzo The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders Eur. J. Pharmacol. 480 2003 133 150
56. S.D. Van Leeuwen, O.B. Bonne, and Y. Avraham Separation as a new animal model for self induced weight loss Physiol. Behav. 62 1997 77 81
57. K. Varga, J.A. Wagner, D.T. Bridgen, and G. Kunos Platelet and macrophage derived endogenous cannabinoids are involved in endotoxin-induced hypotension FASEB J. 12 1998 1035 1044
58. C. Yurdaydin, Y. Li, J.-H. Ha, R. Rothman, and A.S. Basile Brain and plasma levels of opioid peptides are altered in rats with thioacetamide induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid receptor antagonists J. Pharmacol. Exp. Ther. 273 1995 185 192
59. C. Yurdaydin, A.M. Herneth, A. Puspok, P. Steindl, E.A. Singer, and P. Ferenci Modulation of hepatic encephalopathy in rats with thioacetamide induced acute liver failure by serotonin antagonists Eur. J. Gastroenterol. Hepatol. 8 1996 667 671
60. C. Zimmerman, P. Ferenci, C. Pifl, C. Yurdaydin, J. Ebner, H. Lassman, E. Roth, and H. Hortnagel Hepatic encephalopathy in thioacetamide induced acute liver failure in rats: characterization of an improved animal model and study of amino acid-ergic neurotransmission Hepatology 9 1989 594 601